Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer

Abstract

Ceritinib was highly active in patients with advanced, ALK-rearranged NSCLC, including those who had had disease progression during crizotinib treatment, regardless of the presence of resistance mutations in ALK. (Funded by Novartis Pharmaceuticals and others; ClinicalTrials.gov number, NCT01283516.).

Keywords

MeSH Terms

Affiliated Institutions

• KU Leuven BE
• Peter MacCallum Cancer Centre AU
• Massachusetts General Hospital US
• University of Duisburg-Essen DE
• Deutschen Konsortium für Translationale Krebsforschung
• Huntsman Cancer Institute US
• European Institute of Oncology IT
• Hebron University PS
• University of Colorado Denver US
• Integrated Oncology (United States) US
• Fox Chase Cancer Center US
• Istituti di Ricovero e Cura a Carattere Scientifico IT
• University Hospital Cologne DE
• Genome Institute of Singapore SG
• University of Washington US
• Novartis (United States) US
• Memorial Sloan Kettering Cancer Center US
• Seattle University US
• Princess Margaret Cancer Centre CA
• Seoul National University Hospital KR
• Heidelberg University DE
• German Center for Lung Research DE

Related Publications